Clinical Trials
10 trialsNCT04535401 2024-10-10
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00061932 2021-02-02
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
National Cancer Institute (NCI)
Phase 2 Completed
NCT00941655 2019-11-13
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00062374 2017-07-06
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
National Cancer Institute (NCI)
Phase 2 Completed
NCT00084617 2015-05-01
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00991952 2014-05-26
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005607 2013-12-19
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00031681 2013-09-30
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Phase 1 Completed
NCT00134095 2013-09-17
S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00084604 2013-06-04
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
National Cancer Institute (NCI)
Phase 2 Completed